Lut Van Damme

FHI 360, USA 0000-0003-4921-1880

Lut Van Damme obtained her Medical degree in Belgium in 1988. She worked as a Physician with Doctors without Borders in Mozambique during the civil war and famine and in a refugee camp in Thailand with a UN organization, before working as a Physician at the STI/HIV/AIDS Department of the Institute of Tropical Medicine in Antwerp, Belgium (ITM). In that position, she did her first work in vaginal microbicide research. In 1994-1995, she obtained an M.S. degree in epidemiology from the London School of Hygiene and Tropical Medicine and, when finished, became the overall Principal Investigator for the phase III HIV prevention trial with COL-1492, a nonoxynol-9 containing gel. The results of this trial gave the final outcome for N-9, that is, the product cannot be used to prevent HIV. In 2001, Dr. Van Damme moved to the USA and started working for CONRAD, a not-for-profit organization in Arlington, Va, and was involved in research on contraception and women initiated HIV prevention methods. She obtained her Ph.D. degree at the University of Gent (Belgium) in 2004. At CONRAD, she was the overall Principal Investigator for the phase III trial with cellulose sulfate, an entry inhibitor assessed as a potential HIV prevention gel. In October 2007, after the closure of the cellulose sulfate trial, she took on a new position at FHI 360, Washington, DC. She was the Principal Investigator of FEM-PrEP, a PrEP trial to assess the effect of Truvada on HIV acquisition among high-risk women in Eastern and Southern Africa which was published in the New England Journal of Medicine. Dr. Van Damme has been involved in several microbicide safety trials and participated in many working groups such as biomedical HIV prevention research. She has published multiple articles.

Biography Updated on 2 December 2012

Scholarly Contributions [Data Provided by scopus]

download